[go: up one dir, main page]

NO20061705L - Anvendelse av agomelatin for a fremstille medikamenter tiltenkt for behandlingen av bipolare lidelser - Google Patents

Anvendelse av agomelatin for a fremstille medikamenter tiltenkt for behandlingen av bipolare lidelser

Info

Publication number
NO20061705L
NO20061705L NO20061705A NO20061705A NO20061705L NO 20061705 L NO20061705 L NO 20061705L NO 20061705 A NO20061705 A NO 20061705A NO 20061705 A NO20061705 A NO 20061705A NO 20061705 L NO20061705 L NO 20061705L
Authority
NO
Norway
Prior art keywords
bipolar disorders
agomelatine
manufacture
treatment
drugs intended
Prior art date
Application number
NO20061705A
Other languages
English (en)
Other versions
NO336010B1 (no
Inventor
Christian De Bodinat
Elisabeth Mocaer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061705(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20061705L publication Critical patent/NO20061705L/no
Publication of NO336010B1 publication Critical patent/NO336010B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Den foreliggende oppfirmelse vedrører anvendelsen av agomelatin, eller N-[2-(7-metoksy-l- naftyl)etyl]acetamid, alene eUer i assosiasjon, for å fremstille medikamenter tiltenkt for behandlingen av bipolare lidelser, spesielt bipolare hdelser av type I og II, og mer spesielt bipolare lidelser av type I.
NO20061705A 2005-04-20 2006-04-18 Anvendelse av agomelatin for å fremstille et medikament tiltenkt for behandlingen av bipolare lidelser, farmasøytiske sammensetninger og assosiasjoner omfattende agomelatin, farmasøytiske sammensetninger omfattende en assosiasjon og anvendelse derav NO336010B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (2)

Publication Number Publication Date
NO20061705L true NO20061705L (no) 2006-10-23
NO336010B1 NO336010B1 (no) 2015-04-20

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061705A NO336010B1 (no) 2005-04-20 2006-04-18 Anvendelse av agomelatin for å fremstille et medikament tiltenkt for behandlingen av bipolare lidelser, farmasøytiske sammensetninger og assosiasjoner omfattende agomelatin, farmasøytiske sammensetninger omfattende en assosiasjon og anvendelse derav

Country Status (40)

Country Link
US (1) US7947743B2 (no)
EP (1) EP1714647B1 (no)
JP (2) JP4580364B2 (no)
KR (2) KR100835451B1 (no)
CN (2) CN102038669A (no)
AP (1) AP2656A (no)
AR (1) AR057277A1 (no)
AT (1) ATE491443T1 (no)
AU (1) AU2006201655B2 (no)
BR (1) BRPI0601285A8 (no)
CA (1) CA2544136C (no)
CR (1) CR9426A (no)
CY (1) CY1111257T1 (no)
DE (1) DE602006018822D1 (no)
DK (1) DK1714647T3 (no)
EA (1) EA013462B1 (no)
ES (1) ES2357901T3 (no)
FR (1) FR2884714B1 (no)
GE (1) GEP20094651B (no)
GT (1) GT200600141A (no)
HR (1) HRP20110083T1 (no)
IL (1) IL186373A (no)
JO (1) JO2666B1 (no)
MA (1) MA28266A1 (no)
ME (1) ME01951B (no)
MY (1) MY143171A (no)
NO (1) NO336010B1 (no)
NZ (1) NZ546630A (no)
PE (1) PE20061337A1 (no)
PL (1) PL1714647T3 (no)
PT (1) PT1714647E (no)
RS (1) RS51659B (no)
SG (1) SG126868A1 (no)
SI (1) SI1714647T1 (no)
TN (1) TNSN07364A1 (no)
TW (2) TWI318115B (no)
UA (1) UA83681C2 (no)
UY (1) UY29470A1 (no)
WO (1) WO2006111653A1 (no)
ZA (1) ZA200603160B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO338079B1 (no) * 2005-09-09 2016-07-25 Servier Lab Blanding mellom agomelatin og et tymoregulerende middel til behandling av psykiske lidelser

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
BR0207832A (pt) * 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO338079B1 (no) * 2005-09-09 2016-07-25 Servier Lab Blanding mellom agomelatin og et tymoregulerende middel til behandling av psykiske lidelser

Also Published As

Publication number Publication date
NO336010B1 (no) 2015-04-20
MY143171A (en) 2011-03-31
BRPI0601285A (pt) 2006-12-19
DE602006018822D1 (de) 2011-01-27
KR100835451B1 (ko) 2008-06-09
UY29470A1 (es) 2006-05-31
CA2544136A1 (fr) 2006-10-20
US7947743B2 (en) 2011-05-24
TW200716083A (en) 2007-05-01
GT200600141A (es) 2006-11-22
ATE491443T1 (de) 2011-01-15
GEP20094651B (en) 2009-03-25
SI1714647T1 (sl) 2011-03-31
KR20080028389A (ko) 2008-03-31
RS51659B (sr) 2011-10-31
AU2006201655B2 (en) 2009-04-23
CA2544136C (fr) 2012-02-21
JP2010280699A (ja) 2010-12-16
JO2666B1 (en) 2012-06-17
AU2006201655A1 (en) 2006-11-09
MA28266A1 (fr) 2006-11-01
EA013462B1 (ru) 2010-04-30
NZ546630A (en) 2007-09-28
CR9426A (es) 2008-02-21
AP2007004212A0 (en) 2007-10-31
PT1714647E (pt) 2011-01-14
CN1853619B (zh) 2011-02-02
PE20061337A1 (es) 2007-01-27
FR2884714A1 (fr) 2006-10-27
DK1714647T3 (da) 2011-03-07
PL1714647T3 (pl) 2011-05-31
SG126868A1 (en) 2006-11-29
TNSN07364A1 (en) 2008-12-31
TWI318115B (en) 2009-12-11
EP1714647A1 (fr) 2006-10-25
CY1111257T1 (el) 2015-08-05
BRPI0601285A8 (pt) 2021-03-30
UA83681C2 (uk) 2008-08-11
IL186373A0 (en) 2008-08-07
HRP20110083T1 (hr) 2011-03-31
ES2357901T3 (es) 2011-05-03
CN102038669A (zh) 2011-05-04
WO2006111653A1 (fr) 2006-10-26
ME01951B (me) 2011-10-31
AP2656A (en) 2013-05-07
US20060240127A1 (en) 2006-10-26
AR057277A1 (es) 2007-11-28
FR2884714B1 (fr) 2011-05-06
JP4580364B2 (ja) 2010-11-10
IL186373A (en) 2012-06-28
EP1714647B1 (fr) 2010-12-15
HK1093906A1 (en) 2007-03-16
JP2006316056A (ja) 2006-11-24
JP5341037B2 (ja) 2013-11-13
CN1853619A (zh) 2006-11-01
TW200940049A (en) 2009-10-01
EA200600600A1 (ru) 2006-10-27
KR20060110803A (ko) 2006-10-25
ZA200603160B (en) 2007-06-27

Similar Documents

Publication Publication Date Title
EA200970791A1 (ru) N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ
NO20071774L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av generalisert angstlidelse
WO2007051811A3 (en) Pharmaceutical use of substituted amides
WO2008101907A3 (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
NO20064792L (no) Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.
ATE476418T1 (de) Benzamidderivate und assoziierte verwendungen
NO20064050L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient
NO20061705L (no) Anvendelse av agomelatin for a fremstille medikamenter tiltenkt for behandlingen av bipolare lidelser
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
NO20075989L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom
EA201290485A1 (ru) Производные бензамида
ATE455091T1 (de) Para-alkyl-substituierte n-(4-hydroxy-3-methoxy- benzyl)-zimtsäeureamide und deren verwendung zur herstellung von arzneimitteln
NO20076002L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av periventrikulaer levkomalasi
NO20064049L (no) Ny assosiasjon mellom agomelatin og et tymoregulerende middel og farmasoytiske sammensetninger inneholdende den
NO20064048L (no) Ny assosiasjon mellom agomelatin og en nordadrenalin-reopptaksinhibitor, og farmasoytiske sammensetninger inneholdende den
DE602006021594D1 (de) Verbindung zur prävention und behandlung von links
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
ATE419847T1 (de) Verwendung von acetyl-l-carinitin zur behandlung des fibromyalgischen syndroms

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees